Seguimiento de la paciente con diagnóstico de cáncer de mama. Revisión de la evidencia y abordaje terapéutico en el Instituto Nacional de Cancerología - Colombia

Autores/as

DOI:

https://doi.org/10.35509/01239015.865

Palabras clave:

neoplasias de la mama, estudios de seguimiento, supervivientes de cáncer, diagnóstico precoz, recurrencia local de neoplasia, instituciones oncológicas

Resumen

Los supervivientes de cáncer se definen como aquellos individuos que han completado su tratamiento inicial y no tienen evidencia de la enfermedad. Para el caso de las pacientes supervivientes de cáncer de mama, el seguimiento involucra no sólo la vigilancia de la recaída locorregional y a distancia, así como la tamización de segundos primarios mamarios, sino también la evaluación de los efectos relacionados con las terapias recibidas. Hoy en día, existe controversia sobre cuál debe ser el método, la frecuencia, la duración y tipo de personal de la salud que realice el seguimiento de estas pacientes. Las guías de las distintas sociedades científicas muestran una variabilidad importante en las recomendaciones a este respecto. Este documento pretende revisar la mejor evidencia disponible sobre los procedimientos para la detección de la recaída locorregional, de las metástasis a distancia, de un segundo cáncer de mama contralateral y de los eventos adversos relacionados con los tratamientos para el cáncer de mama. Adicionalmente, se examinan los porcentajes y sitios de recidiva tumoral con relación al estadio clínico y a la biología tumoral.

Biografía del autor/a

Ximena Briceño-Morales, Especialista en entrenamiento en Mastología, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

1. Especialista en entrenamiento en Mastología, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

Andrea Zuluaga-Liberato, Especialista en entrenamiento en Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

2. Especialista en entrenamiento en Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

Clara Briceño-Morales, Especialista en entrenamiento en Cirugía Oncológica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

3. Especialista en entrenamiento en Cirugía Oncológica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

6. Universidad Tecnológica de Pereira, Pereira, Colombia.

Luis Guzmán-Abi-Saab, Unidad Funcional de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

4. Unidad Funcional de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

Jesús Oswaldo Sánchez-Castillo, Unidad de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

5. Unidad de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

Ricardo Brugés-Maya, Unidad de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

5. Unidad de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

Carlos Lehmann-Mosquera, Unidad Funcional de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

4. Unidad Funcional de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

Mauricio García-Mora, Unidad Funcional de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

4. Unidad Funcional de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

Javier Ángel-Aristizábal, Unidad Funcional de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

4. Unidad Funcional de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

Iván Fernando Mariño-Lozano, Unidad Funcional de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

4. Unidad Funcional de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

Carlos Alfonso Duarte-Torres, Unidad Funcional de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

4. Unidad Funcional de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

Fernando Contreras-Mejía, Unidad de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

5. Unidad de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

Eduardo Rojas, Unidad de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

5. Unidad de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

Sandra E. Diaz-Casas, Unidad Funcional de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

4. Unidad Funcional de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.

Referencias bibliográficas

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660

National Cancer Institute. National Cancer Institute SEER Cancer Statistics Review 1975-2010. Natl Cancer Inst. 2013;103(7). Available from: https://seer.cancer.gov/archive/csr/1975_2010/

Cheung WY, Neville BA, Cameron DB, Cook EF, Earle CC. Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol. 2009;27(15):2489–95. https://doi.org/10.1200/jco.2008.20.3232

American Society of Clinical Oncology. Sobrevivencia al cáncer. CancerNet. 2013;1–32. Available from: www.cancer.net/ espanol

Freedman RA, Keating NL, Partridge AH, Muss HB, Hurria A, Winer EP. Surveillance mammography in older patients with breast cancer—Can we ever stop? JAMA Oncol. 2017;3(3):402. https://doi.org/10.1001/jamaoncol.2016.3931

Sisler J, Chaput G, Sussman J, Ozokwelu E. Follow-up after treatment for breast cancer: Practical guide to survivorship care for family physicians. Can Fam Physician. 2016;62(10):805-811. PMID: 27737976.

Bansal GJ, Telford T, Pinto K. Breast cancer survivors: Is routine “mammograms only” enough or is it time for personalised follow up?. Int J Cancer Clin Res. 2019;6:116. https://doi.org/10.23937/2378-3419/1410116

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–46. https://doi.org/10.1056/NEJMoa1701830

Montgomery DA, Krupa K, Cooke TG. Follow-up in breast cancer: Does routine clinical examination improve outcome? A systematic review of the literature. Br J Cancer. 2007;97(12):1632–41. https://doi.org/10.1038/sj.bjc.6604065

Waks AG, Winer EP. Breast cancer treatment: A review. JAMA - J Am Med Assoc. 2019;321(3):288–300. https://doi.org/10.1001/jama.2018.19323

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level metaanalysis of randomised trials. Lancet. 2011;378(9793):771–84. https://doi.org/10.1016/S0140-6736(11)60993-8

Strasser-Weippl K, Horick N, Smith IE, O’Shaughnessy J, Ejlertsen B, Boyle F, et al. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res. 2015;17(1):56. https://doi.org/10.1186/s13058-015-0568-1

Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372(2):134–41. https://doi.org/10.1056/NEJMoa1406281

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72. https://doi.org/10.1016/S0140-6736(13)62422-8

Díaz‐Casas SE, Castilla‐Tarra JA, Pena‐Torres E, Orozco‐Ospino M, Mendoza‐Diaz S, Nuñez‐Lemus M, et al. Pathological response to neoadjuvant chemotherapy and the molecular classification of locally advanced breast cancer in a Latin American cohort. Oncologist. 2019;24(12):1–11. https://doi.org/10.1634/theoncologist.2019-0300

Kokko R, Hakama M, Holli K. Follow-up cost of breast cancer patients with localized disease after primary treatment: A randomized trial. Breast Cancer Res Treat. 2005;93(3):255–60. https://doi.org/10.1007/s10549-005-5199-2

Ruddy KJ, Partridge AH. Approach to the patient following treatment for breast cancer. UpToDate. 2020. Available from: https://www.uptodate.com/contents/approach-tothe-patient-following-treatment-for-breast-cancer

Lafranconi A, Pylkkänen L, Deandrea S, Bramesfeld A, Lerda D, Neamtiu L, et al. Intensive follow-up for women with breast cancer: Review of clinical, economic and patient’s preference domains through evidence to decision framework. Health Qual Life Outcomes. 2017;15(1). https://doi.org/10.1186/s12955-017-0779-5

de Bock GH, Bonnema J, van Der Hage J, Kievit J, van de Velde CJH. Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: A metaanalysis and systematic review. Vol. 22, Journal of Clinical Oncology. 2004. https://doi.org/10.1200/JCO.2004.06.080

Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2016;34(6):611–35. https://doi.org/10.1200/JCO.2015.64.3809

Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2013;31(7):961–5. https://doi.org/10.1200/JCO.2012.45.9859

Gulliford T, Opomu M, Wilson E, Hanham I, Epstein R. Popularity of less frequent follow up for breast cancer in randomised study: Initial findings from the hotline study. Br Med J. 1997;314(7075):174–7. https://doi.org/10.1136/bmj.314.7075.174

Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006;24(31):5091–7. https://doi.org/10.1200/JCO.2006.08.8575

Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013;22(3):203–10. https://doi.org/10.1016/j.breast.2013.03.006

Grunfeld E, Noorani H, McGahan L, Paszat L, Coyle D, Van Walraven C, et al. Surveillance mammography after treatment of primary breast cancer: A systematic review. Breast. 2002;11(3):228–35. https://doi.org/10.1054/brst.2001.0404

De La Rochefordière A, Mouret-Fourme E, Asselain B, Scholl SM, Campana F, Broët P, et al. Metachronous contralateral breast cancer as first event of relapse. Int J Radiat Oncol Biol Phys. 1996;36(3):615–21. https://doi.org/10.1016/s0360-3016(96)00372-0

Lu W, Schaapveld M, Jansen L, Bagherzadegan E, Sahinovic MM, Baas PC, et al. The value of surveillance mammography of the contralateral breast in patients with a history of breast cancer. Eur J Cancer . 2009;45(17):3000–7. https://doi.org/10.1016/j.ejca.2009.08.007

Ciatto S, Guido M, Marco Z. Prognostic impact of the early detection of metachronous contralateral breast cancer. Eur J Cancer. 2004;40(10):1496–501. https://doi.org/10.1016/j.ejca.2004.03.010

Lu WL, Jansen L, Post WJ, Bonnema J, Van De Velde JC, De Bock GH. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: A meta-analysis. Breast Cancer Res Treat. 2009;114(3):403–12. https://doi.org/10.1007/s10549-008-0023-4

Mellink WAM, Holland R, Hendriks JH, Peeters PHM, Rutgers T, Daal V. The Contribution. 1987;1844–8. https://doi.org/10.1002/1097-0142(19910401)67:7<1844::aidcncr2820670705>3.0.co;2-w

Gutter Z. Cancer of the remaining breast: radiologic contribution to diagnosis. Can Med Assoc J. 1976;114(1):27–30. PMID: 943222.

Senofsky GM, Wanebo HJ, Wilhelm MC, Pope TL, Fechner RE, Broaddus W, et al. Has monitoring of the contralateral breast improved the prognosis in patients treated for primary breast cancer? Cancer. 1986;57(3):597–602. https://doi.org/10.1002/1097-0142(19860201)57:3%3C597::aidcncr2820570334%3E3.0.co;2-5

Houssami N, Ciatto S. Mammographic surveillance in women with a personal history of breast cancer: How accurate? How effective? Breast. 2010;19(6):439–45. http://doi.org/10.1016/j.breast.2010.05.010

Houssami N, Abraham LA, Miglioretti DL, Sickles EA, Kerlikowske K, Buist DSM, et al. Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer. JAMA - J Am Med Assoc. 2011;305(8):790–9. https://doi.org/10.1001/jama.2011.188

Ciatto S, Cataliotti L, Pacini P, Distante V, Bianchi S, Simoncini R, et al. Cancer reoccurrence in the conserved breast: Diagnostic features in a consecutive series of 102 cases. Int J Oncol. 1993;3(2):337–9. https://doi.org/10.3892/ijo.3.2.337

Wapnir IL, Alden-Corbett S, Zicherman B, Greco RS. Mammographic changes following biopsy and lumpectomy-breast irradiation. N J Med. 1993;90(1): 55-9. PMID: 8380491.

Lash TL, Fox MP, Silliman RA. Reduced mortality rate associated with annual mammograms after breast cancer therapy. Breast J. 2006;12(1):2–6. https://doi.org/10.1111/j.1075-122X.2006.00177.x

Lash TL, Fox MP, Buist DSM, Wei F, Field TS, Frost FJ, et al. Mammography surveillance and mortality in older breast cancer survivors. J Clin Oncol. 2007;25(21):3001–6. https://doi.org/10.1200/JCO.2006.09.9572

Schootman M, Jeffe DB, Lian M, Aft R, Gillanders WE. Surveillance mammography and the risk of death among elderly breast cancer patients. Breast Cancer Res Treat. 2008;111(3). https://doi.org/10.1007/s10549-007-9795-1

Paszat L, Sutradhar R, Grunfeld E, Gainford C, Benk V, Bondy S, et al. Outcomes of surveillance mammography after treatment of primary breast cancer: A population-based case series. Breast Cancer Res Treat. 2009;114(1):169–78. https://doi.org/10.1007/s10549-008-9986-4

Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast cancer. Version 5.2020. NCCN; 2020. Available from: https://www2.trikobe.org/nccn/guideline/breast/english/breast.pdf

Moy L, Newell MS, Mahoney MC, Bailey L, Barke LD, Carkaci S, et al. ACR appropriateness criteria stage I breast cancer: initial workup and surveillance for local recurrence and distant metastases in asymptomatic women. J Am Coll Radiol. 2016;13(11):e43–52. http://doi.org/10.1016/j.jacr.2016.09.023

Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and followup. Ann Oncol. 2015;26. https://doi.org/10.1093/annonc/mdv298

National Institute for Health and Care Excellence. Review of clinical guideline (CG80): breast cancer. 2012. Available from: https://www.nice.org.uk/guidance/cg80

Lam DL, Houssami N, Lee JM. Imaging surveillance after primary breast cancer treatment. Am J Roentgenol. 2017;208(3):676–86. Available from: http://www.doi.org/10.2214/AJR.16.16300

Arasu VA, Joe BN, Lvoff NM, Leung JWT, Brenner RJ, Flowers CI, et al. Benefit of semiannual ipsilateral mammographic surveillance following breast conservation therapy. Radiology. 2012;264(2):371–7. https://doi.org/10.1148/radiol.12111458

McNaul D, Darke M, Garg M, Dale P. An evaluation of postlumpectomy recurrence rates: Is follow-up every 6 months for 2 years needed? J Surg Oncol. 2013;107(6):597–601. https://doi.org/10.1002/jso.23298

Allen A, Cauthen A, Vaughan J, Dale P. The clinical utility and cost of postoperative mammography completed within one year of breast conserving therapy: Is it worth It? Am Surg. 2017;83(8):871-874. PMID: 28822394.

Hymas R V., Gaffney DK, Parkinson BT, Belnap TW, Sause WT. Is short-interval mammography necessary after breast conservation surgery and radiation treatment in breast cancer patients? Int J Radiat Oncol Biol Phys . 2012;83(2):519–24. http://doi.org/10.1016/j.ijrobp.2011.07.029

Lin K, Eradat J, Mehta NH, Bent C, Lee SP, Apple SK, et al. Is a short-interval postradiation mammogram necessary after conservative surgery and radiation in breast cancer? Int J Radiat Oncol Biol Phys. 2008;72(4):1041–7. https://doi.org/10.1016/j.ijrobp.2008.02.017

Yoon JH, Kim MJ, Kim EK, Moon HJ. Imaging surveillance of patients with breast cancer after primary treatment: Current recommendations. Korean J Radiol. 2015;16(2):219–28. https://doi.org/10.3348/kjr.2015.16.2.219

Berg WA, Bandos AI, Mendelson EB, Lehrer D, Jong RA, Pisano ED. Ultrasound as the primary screening test for breast cancer: Analysis from acrin 6666. J Natl Cancer Inst. 2016;108(4):1–8. https://doi.org/10.1093/jnci/djv367

Bromley L, Xu J, Loh SW, Chew G, Lau E, Yeo B. Breast ultrasound in breast cancer surveillance; incremental cancers found at what cost? Breast. 2020;54:272–7. https://doi.org/10.1016/j.breast.2020.11.007

Kim SY, Cho N, Kim SY, Choi Y, Kim ES, Ha SM, et al. Supplemental breast US screening in women with a personal history of breast cancer: A matched cohort study. Radiology. 2020;295(1):54–63. https://doi.org/10.1148/radiol.2020191691

Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA - J Am Med Assoc. 2012;307(13):1394–404. https://doi.org/10.1001/jama.2012.388

Lehman CD, Lee JM, DeMartini WB, Hippe DS, Rendi MH, Kalish G, et al. Screening MRI in women with a personal history of breast cancer. J Natl Cancer Inst. 2016;108(3):1–8. https://doi.org/10.1093/jnci/djv349

Quinn EM, Coveney AP, Redmond HP. Use of magnetic resonance imaging in detection of breast cancer recurrence: A systematic review. Ann Surg Oncol. 2012;19(9):3035–41. https://doi.org/10.1245/s10434-012-2341-3

Wernli KJ, Ichikawa L, Kerlikowske K, Buist DSM, Brandzel SD, Bush M, et al. Surveillance breast MRI and mammography: Comparison in women with a personal history of breast cancer. Radiology. 2019;292(2):311–8. https://doi.org/10.1148/radiol.2019182475

Barnsley GP, Grunfeld E, Coyle D, Paszat L. Surveillance mammography following the treatment of primary breast cancer with breast reconstruction: A systematic review. Plast Reconstr Surg. 2007;120(5):1125–32. https://doi.org/10.1097/01.prs.0000279143.66781.9a

Moschetti I, Cinquini M, Lambertini M, Levaggi A, Liberati A. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2016;2016(5). https://doi.org/10.1002/14651858.CD001768.pub3

Ghezzi P, Magnanini S. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. JAMA. 1994;271:1587–92. https://doi.org/10.1001/jama.1994.03510440047031

Del Turco MR, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer: A randomized trial. JAMA J Am Med Assoc. 1994;271(20):1593–7. https://doi.org/10.1001/jama.271.20.1593

Bonilla-Sepúlveda. Tumor markers in breast cancer. Systematic review. Ginecol Obs Mex. 2020;88(12):860–9. https://doi.org/10.24245/gom.v88i12.4269

Hollingsworth MA, Swanson BJ. Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer. 2004;4(1):45–60. https://doi.org/10.1038/nrc1251

Molina R, Zanón G, Filella X, Moreno F, Jo J, Daniels M, et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat. 1995;36(1):41–8. https://doi.org/10.1007/BF00690183

Chan DW, Beveridge RA, Muss H, Fritsche HA, Hortobagyi G, Theriault R, et al. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol. 1997;15(6):2322–8. https://doi.org/10.1200/jco.1997.15.6.2322

Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localised breast cancer: A prospective study. Eur J Cancer. 2002;38(9):1189–93. https://doi.org/10.1016/s0959-8049(01)00429-4

Mariani L, Miceli R, Michilin S, Gion M. Serial determination of CEA and CA 15.3 in breast cancer follow-up: An assessment of their diagnostic accuracy for the detection of tumour recurrences. Biomarkers. 2009;14(2):130–6. https://doi.org/10.1080/13547500902770090

Kovner F, Merimsky O, Hareuveni M, Wigler N, Chaitchik S. Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial. Cancer Chemother Pharmacol. 1994;35(1):80–3. https://doi.org/10.1007/BF00686288

Merimsky O, Kovner F, Inbar M, Hareuveni M, Rosenboim Y, Chaitchik S. Tamoxifen for disease-negative but MCApositive breast cancer patients. Oncol Rep. 1997;4(4):843–7. https://doi.org/10.3892/or.4.4.843

Nicolini A, Anselmi L, Michelassi C, Carpi A. Prolonged survival by “early” salvage treatment of breast cancer patients: A retrospective 6-year study. Br J Cancer. 1997;76(8):1106–11. https://doi.org/10.1038/bjc.1997.515

Nicolini A, Carpi A, Michelassi C, Spinelli C, Conte M, Miccoli P, et al. “Tumour marker guided” salvage treatment prolongs survival of breast cancer patients: Final report of a 7-year study. Biomed Pharmacother. 2003;57(10):452–9. https://doi.org/10.1016/j.biopha.2003.09.004

Sparano JA, Lynn Henry N. Surveillance after treatment of localized breast cancer: Time for reappraisal? J Natl Cancer Inst. 2019;111(4):339–41. https://doi.org/10.1093/jnci/djy153

Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, De Gregorio A, et al. Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. J Natl Cancer Inst. 2019;111(4):380–7. https://doi.org/10.1093/jnci/djy152

Sparano J, O’Neill A, Alpaugh K, Wolff AC, Northfelt DW, Dang CT, et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: A secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(12):1700–6. https://doi.org/10.1001/jamaoncol.2018.2574

Pedrazzini A, Gelber R, Isley M, Castiglione M, Goldhirsch A. First repeated bone scan in the observation of patients with operable breast cancer. J Clin Oncol. 1986;4(3):389–94. https://doi.org/10.1200/JCO.1986.4.3.389

Salani R, Andersen BL. Gynecologic care for breast cancer survivors: Assisting in the transition to wellness. Am J Obstet Gynecol. 2012;206(5):390–7. http://doi.org/10.1016/j.ajog.2011.10.858

Tevaarwerk A, Denlinger CS, Sanft T, Ansbaugh SM, Armenian S, Baker KS, et al. Survivorship, Version 1.2021. J Natl Compr Canc Netw. 2021;19(6):676-685. https://doi.org/10.6004/jnccn.2021.0028

Kokko R, Hakama M, Holli K. Role of chest X-ray in diagnosis of the first breast cancer relapse: A randomized trial. Breast Cancer Res Treat. 2003;81(1):33–9. https://doi.org/10.1023/A:1025419114857

Hurria A, Leung D, Trainor K, Norton L, Hudis C. Screening chest imaging studies are not effective in the follow-up of breast cancer patients. J Oncol Manag. 2003;12(5): 13-5. PMID: 14619990.

Yang HL, Liu T, Wang XM, Xu Y, Deng SM. Diagnosis of bone metastases: A meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol. 2011;21(12):2604–17. https://doi.org/10.1007/s00330-011-2221-4

Drotman MB, Machnicki SC, Schwartz LH, Winston CB, Yoo HH, Panicek DM. Breast cancer: Assessing the use of routine pelvic CT in patient evaluation. Am J Roentgenol. 2001;176(6):1433–6. https://doi.org/10.2214/ajr.176.6.1761433

Pennant M, Takwoingi Y, Pennant L, Davenport C, Fry-Smith A, Eisinga A, et al. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess (Rockv). 2010;14(50):1–120. https://doi.org/10.3310/hta14500

Henry LN, Hayes DF, Ramsey SD, Hortobagyi GN, Barlow WE, Gralow JR. Promoting quality and evidence-based care in early-stage breast cancer follow-up. J Natl Cancer Inst. 2014;106(4):1–7. https://doi.org/10.1093/jnci/dju034

Bradley R, Burrett J, Clarke M, Davies C, Duane F, Evans V, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52. http://doi.org/10.1016/S0140-6736(15)61074-1

Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(31):2916–46. https://doi.org/10.1200/JCO.19.01696

Committee Opinion No. 601. Tamoxifen and uterine cancer. Obstet Gynecol. 2014;123(6):1394–7. https://doi.org/10.1097/01.aog.0000450757.18294.cf

Fung MFK, Reid A, Faught W, Le T, Chenier C, Verma S, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol. 2003;91(1):154–9. https://doi.org/10.1016/s0090-8258(03)00441-4

Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular disease and breast cancer: Where these entities intersect: A scientific statement from the American Heart Association. Circulation. 2018;137(8). https://www.doi.org/10.1161/CIR.0000000000000556

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377(2):122–31. https://www.doi.org/10.1056/NEJMoa1703643

Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063–93. https://doi.org/10.1093/ehjci/jeu192

Ministerio de Salud y Protección Social, Colombia. Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias en la población mayor de 18 años. 2014. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/INEC/IETS/GPC-Dislipidemi-completa.pdf

Grunfeld E, Levine MN, Julian JA, Coyle D, Szechtman B, Mirsky D, et al. Randomized trial of long-term follow-up for early-stage breast cancer: A comparison of family physician versus specialist care. J Clin Oncol. 2006;24(6):848–55. https://doi.org/10.1200/JCO.2005.03.2235

Grunfeld E, Mant D, Yudkin P, Adewuyi-Dalton R, Cole D, Stewart J, et al. Routine follow up of breast cancer in primary care: Randomised trial. Br Med J. 1996;313(7058):665–9. https://doi.org/10.1136/bmj.313.7058.665

Grunfeld E, Gray A, Mant D, Yudkin P, Adewuyi-Dalton R, Coyle D, et al. Follow-up of breast cancer in primary care vs specialist care: Results of an economic evaluation. Br J Cancer. 1999;79(7–8). https://doi.org/10.1038/sj.bjc.6690197

Grunfeld E, Fitzpatrick R, Mant D, Yudkin P, Adewuyi-Dalton R, Stewart J, et al. Comparison of breast cancer patient satisfaction with follow-up in primary care versus specialist care: Results from a randomized controlled trial. Br J Gen Pract. 1999;49(446):705–10. PMID: 10756611.

Grunfeld E, Yudkin P, Adewuyl-Dalton R, Vessey MP, Mant D. Follow up in breast cancer. Quality of life unaffected by general practice follow up. BMJ. 1995;311(6996):54. https://doi.org/10.1136%2Fbmj.311.6996.54

Spronk I, Korevaar JC, Schellevis FG, Albreht T, Burgers JS. Evidence-based recommendations on care for breast cancer survivors for primary care providers: A review of evidence-based breast cancer guidelines. BMJ Open. 2017;7(12). https://doi.org/10.1136/bmjopen-2016-015118

Walter LC, Schonberg MA. Screening mammography in older women: A review. JAMA - J Am Med Assoc. 2014;311(13):1336–47. https://doi.org/10.1001/jama.2014.2834

VanderWalde N, Jagsi R, Dotan E, Baumgartner J, Browner IS, Burhenn P, et al. NCCN Guidelines insights: Older adult oncology, Version 2.2016. J Natl Compr Cancer Netw. 2016;14(11):1357–70. https://doi.org/10.6004/jnccn.2016.0146

Freedman RA, Keating NL, Pace LE, Lii J, McCarthy EP, Schonberg MA. Use of surveillance mammography among older breast cancer survivors by life expectancy. J Clin Oncol. 2017;35(27). https://doi.org/10.1200/JCO.2016.72.1209

Montgomery DA, Krupa K, Cooke TG. Alternative methods of follow up in breast cancer: A systematic review of the literature. Br J Cancer. 2007;96(11):1625–32. https://doi.org/10.1038/sj.bjc.6603771

Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194-1220. https://doi.org/10.1093/annonc/mdz173

Cómo citar

[1]
Briceño Morales, X. et al. 2023. Seguimiento de la paciente con diagnóstico de cáncer de mama. Revisión de la evidencia y abordaje terapéutico en el Instituto Nacional de Cancerología - Colombia. Revista Colombiana de Cancerología. 27, (feb. 2023), 52–71. DOI:https://doi.org/10.35509/01239015.865.

Descargas

Los datos de descargas todavía no están disponibles.

Descargas

Publicado

01-02-2023
Crossref Cited-by logo